STOCK TITAN

Rockwell Medical (RMTI) Stock News

RMTI NASDAQ

Rockwell Medical develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Company news centers on financial and operational results, gross margin and cash flow trends, supply-chain and distribution initiatives, and customer activity tied to dialysis clinics and large dialysis-service providers.

Recurring updates also cover product purchase agreements, expanded delivery capabilities in U.S. regions, additions to the customer clinic footprint, operational changes aimed at improving gross profit, and corporate communications such as earnings release schedules and workplace-related announcements.

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) reported third-quarter 2026 net sales of $19.1 million, up from the same period in 2025. Sales rose 20%, driven by existing customers and new customers in the western United States. Gross profit increased 37% to $3.1 million, and gross margin rose to 16% from 14%. Net loss widened to $2.324 million from $1.753 million, while adjusted EBITDA, a non-GAAP earnings measure, fell to negative $267,000 from positive $50,000.

Nine-month sales increased 7% to $54.2 million, while net loss widened to $5.101 million from $4.760 million. Cash, cash equivalents and investments were $22.5 million, down from $24.8 million at June 30. After quarter-end, Rockwell signed an agreement to acquire Vantive’s hemodialysis equipment and concentrates business, including its Medolla, Italy manufacturing campus. Rockwell projects combined annual revenue of $400 million to $450 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
-
Rhea-AI Summary

Vantive agreed to sell most of its hemodialysis assets and associated operations to Rockwell Medical (Nasdaq: RMTI) under a definitive agreement.

The transaction covers hemodialysis concentrates, monitors and water treatment systems, along with related consumables and technical services. Ownership of Vantive's manufacturing facility in Medolla, Italy, will transfer to Rockwell Medical upon completion. Vantive's dialyzer portfolio, including Theranova, is excluded.

The companies expect the transaction to close in mid-2027, subject to required regulatory approvals and customary closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.08%
Tags
none
-
Rhea-AI Summary

Rockwell Medical (RMTI) signed an agreement to acquire Vantive’s hemodialysis business assets for a base purchase price of $125 million. The acquisition covers concentrates, dialysis machines, water treatment systems, related consumables and technical services, plus a manufacturing campus in Medolla, Italy.

The price, subject to customary adjustments, will be financed through two $50 million Vantive term loans and a $25 million convertible note. Vantive may receive up to $45 million more upon specified revenue and EBITDA milestones. Rockwell estimates combined annual revenue could reach $400 million–$450 million. Closing is expected in mid-2027, subject to required regulatory approvals and other closing conditions. Rockwell withdrew its 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow because of projected transaction-related and financing-related expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.08%
Tags
Rhea-AI Summary

Rockwell Medical (RMTI) will release its third-quarter 2026 financial and operational results on November 12, 2026. The results cover the quarter ended September 30, 2026. A press release is scheduled for 6:00 a.m. EST, followed by a live webcast at 8:00 a.m. EST. CEO Mark Strobeck and CFO Jesse Neri will discuss the results and take questions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
earnings date
-
Rhea-AI Summary

Rockwell Medical (RMTI) will exhibit its hemodialysis concentrates portfolio at American Society of Nephrology Kidney Week, held October 21–25, 2026.

The company will exhibit in Booth #1049 at the Colorado Convention Center in Denver, Colorado. Information about its dialysis concentrates portfolio is available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
Rhea-AI Summary

Rockwell Medical (RMTI) ranked No. 16 on Fortune’s 2026 Best Workplaces in Manufacturing & Production list in the small & medium category.

Great Place to Work and Fortune named the company among 50 workplaces in the category. This is its third consecutive annual recognition, following rankings of No. 50 in 2024 and No. 40 in 2025. Over ninety percent of employees said they were proud of what the company accomplishes, proud to tell others they work there, and that working there has special meaning to them.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.45%
Tags
none
Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) reported second quarter 2026 net sales of $17.8 million, up 11% from $16.1 million a year earlier, driven by new customers in the Western U.S. and higher purchasing from existing accounts. Gross profit rose 30% to $3.2 million, with gross margin expanding to 18% from 16% on lower manufacturing costs and higher volume. Net loss narrowed to $1.2 million versus $1.5 million in Q2 2025 and $1.6 million in Q1 2026; Adjusted EBITDA was -$0.2 million, flat year over year. The company generated $2.1 million of operating cash flow, ending June 30, 2026 with $24.8 million in cash, cash equivalents and investments. Operating highlights included new or extended multi-year product purchase agreements with Heritage Dialysis and aQua Dialysis, a 1-for-10 reverse stock split effective July 1, 2026, and subsequent confirmation of regained compliance with Nasdaq’s minimum bid requirement. Rockwell reiterated its 2026 guidance for net sales of $70–$75 million, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
-
Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) appointed Brian Cox as Vice President, Quality and Regulatory Compliance, strengthening leadership over its global hemodialysis product portfolio. According to the company, Cox brings more than 20 years of healthcare experience across medical device development, manufacturing, quality, regulatory compliance, operations, and program management.

His background includes senior roles at Abbott, Johnson & Johnson, and growth-focused medical device manufacturers, with expertise in Class I–III devices, regulated manufacturing, audit oversight, and product launch readiness. The company views this hire as supporting its long-term strategy, compliance, and scalable quality systems in the dialysis market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). The company’s shares maintained a closing bid price of at least $1.00 from July 1, 2026 to July 15, 2026, leading Nasdaq to close the compliance matter. Rockwell Medical is now in full compliance with all Nasdaq continued listing requirements, and its stock continues to trade on the Nasdaq Capital Market under the ticker RMTI.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced it will release its financial and operational results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. A press release will be issued at 6:00 a.m. ET, followed by a live webcast at 8:00 a.m. ET via www.RockwellMed.com/Results, featuring President and CEO Mark Strobeck and CFO Jesse Neri, with a Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.60%
Tags
earnings date

FAQ

What is the current stock price of Rockwell Medical (RMTI)?

Rockwell Medical (RMTI) last closed at $6.61.

What is the market cap of Rockwell Medical (RMTI)?

The market cap of Rockwell Medical (RMTI) is approximately $26.3M.